BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $214
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $180 to $214.
July 19, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie and raises the price target from $180 to $214.
The raised price target and maintained Outperform rating from a reputable analyst at BMO Capital is likely to positively influence investor sentiment and drive short-term price appreciation for AbbVie.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100